CEO Dipal Doshi (Entrada)

Piv­ot­ing to­ward neu­ro­mus­cu­lar dis­eases and Duchenne, En­tra­da locks down $116M crossover round

A lit­tle over two years since its last $59 mil­lion round, En­tra­da Ther­a­peu­tics is mak­ing some more noise Wednes­day with a nine-fig­ure crossover. And they’ve got a new fo­cus on neu­ro­mus­cu­lar dis­eases, led by Duchenne mus­cu­lar dy­s­tro­phy, as their re­search has broad­ened over the years.

En­tra­da pulled in a $116 mil­lion Se­ries B, with the funds pri­mar­i­ly slat­ed for get­ting its first Duchenne pro­gram in­to the clin­ic. The Boston-based biotech hopes to get past the IND ac­cep­tance phase for the lead can­di­date and then ex­pand in­to oth­er neu­ro­mus­cu­lar ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.